JP2010526827A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526827A5
JP2010526827A5 JP2010507667A JP2010507667A JP2010526827A5 JP 2010526827 A5 JP2010526827 A5 JP 2010526827A5 JP 2010507667 A JP2010507667 A JP 2010507667A JP 2010507667 A JP2010507667 A JP 2010507667A JP 2010526827 A5 JP2010526827 A5 JP 2010526827A5
Authority
JP
Japan
Prior art keywords
formula
composition
pharmaceutically acceptable
acceptable salt
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010507667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526827A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/063088 external-priority patent/WO2008141099A1/en
Publication of JP2010526827A publication Critical patent/JP2010526827A/ja
Publication of JP2010526827A5 publication Critical patent/JP2010526827A5/ja
Pending legal-status Critical Current

Links

JP2010507667A 2007-05-09 2008-05-08 治療用化合物 Pending JP2010526827A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92841607P 2007-05-09 2007-05-09
US92834507P 2007-05-09 2007-05-09
PCT/US2008/063088 WO2008141099A1 (en) 2007-05-09 2008-05-08 Therapeutic compounds

Publications (2)

Publication Number Publication Date
JP2010526827A JP2010526827A (ja) 2010-08-05
JP2010526827A5 true JP2010526827A5 (enExample) 2011-06-23

Family

ID=39619201

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010507667A Pending JP2010526827A (ja) 2007-05-09 2008-05-08 治療用化合物

Country Status (17)

Country Link
US (3) US8173849B2 (enExample)
EP (2) EP2152651B1 (enExample)
JP (1) JP2010526827A (enExample)
KR (1) KR20100017435A (enExample)
CN (1) CN101687746A (enExample)
AT (1) ATE540010T1 (enExample)
AU (1) AU2008251484A1 (enExample)
BR (1) BRPI0811284A2 (enExample)
CA (1) CA2685813A1 (enExample)
DK (1) DK2152651T3 (enExample)
ES (1) ES2380824T3 (enExample)
IL (1) IL201735A0 (enExample)
MX (1) MX2009012125A (enExample)
MY (1) MY147215A (enExample)
RU (1) RU2470907C2 (enExample)
WO (1) WO2008141099A1 (enExample)
ZA (1) ZA201007602B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101715437B (zh) 2007-05-09 2013-06-12 特色疗法股份有限公司 立体异构异丙酚治疗性化合物
WO2009140275A1 (en) * 2008-05-12 2009-11-19 Pharmacofore, Inc. Analogs of propofol, preparation thereof and use as anesthetics
CN102085185B (zh) * 2010-12-07 2013-04-24 西安力邦制药有限公司 无痛和低注射刺激的新型丙泊酚脂肪乳制剂配方和制备方法
CN102603488B (zh) * 2012-03-06 2017-01-04 云南龙海天然植物药业有限公司 一种制备高纯度丙泊酚的新方法
CN102731265B (zh) * 2012-06-12 2014-12-10 四川百利药业有限责任公司 一种高纯度丙泊酚的制备方法
BR112015009202B1 (pt) * 2012-11-02 2021-01-19 Sumitomo Chemical Company, Limited método para produzir racemato de composto
CN104649867B (zh) * 2013-11-21 2017-02-15 辽宁药联制药有限公司 一种丙泊酚的制备方法
CN105384608B (zh) * 2014-08-22 2019-08-16 四川海思科制药有限公司 一种异丙基苯酚衍生物及其制备方法
CN105384607B (zh) * 2014-08-22 2019-08-16 四川海思科制药有限公司 一种异丙基苯酚衍生物及其制备方法
CN105384604B (zh) * 2014-08-22 2019-07-05 四川海思科制药有限公司 一种异丙基苯酚衍生物及其制备方法
ES2973259T3 (es) * 2014-09-04 2024-06-19 Haisco Innovative Pharmaceutical Pte Ltd Uso de agente de refuerzo del receptor GABAA en la preparación de medicamentos sedantes y anestésicos
CN105820040B (zh) * 2015-01-22 2018-07-24 四川海思科制药有限公司 一种异丙基苯酚衍生物及其制备方法
CN106278947B (zh) * 2015-05-19 2020-03-06 四川海思科制药有限公司 苯酚衍生物的晶型及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2747982A (en) * 1955-05-11 1956-05-29 Dow Chemical Co Method and composition for the control of the growth of vegetation
US4798846A (en) * 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
SU1525139A1 (ru) * 1987-11-10 1989-11-30 Куйбышевский политехнический институт им.В.В.Куйбышева Способ получени о-втор-бутилфенола
ES2087019B1 (es) * 1994-02-08 1997-03-16 Bobel246 S L Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la 5-lipoxigenasa.
US5731356A (en) 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US6254853B1 (en) 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
DE60011053T2 (de) 1999-02-18 2005-05-25 SuperGen, Inc., Dublin An phosphocholin gebundene prodrug-derivate
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6362234B1 (en) 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
WO2002044324A2 (en) 2000-10-06 2002-06-06 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
NZ533536A (en) 2001-12-28 2006-11-30 Mgi Gp Inc Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol such as O-phosphonooxymethyl propofol
US7035343B2 (en) 2002-01-31 2006-04-25 Qualcomm Inc. Closed loop transmit diversity antenna verification using trellis decoding
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
BG65734B1 (bg) 2002-02-22 2009-09-30 Био Терапютикс - Еоод Течен мукоадхезивен фармацевтичен състав
HUP0600241A2 (en) 2002-04-08 2006-07-28 Mgi Gp Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
DE20215415U1 (de) 2002-10-08 2004-02-26 Biotechnologie Gesellschaft Mittelhessen Mbh Wasserlösliche Medikamentenvorstufen von Propofol
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
ZA200504940B (en) 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
AU2003901815A0 (en) 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US7230003B2 (en) 2003-09-09 2007-06-12 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
US20070043121A1 (en) * 2003-09-29 2007-02-22 Brown Milton L Discovery of novel soluble crystalline anesthetics
US7241807B2 (en) 2004-07-12 2007-07-10 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
WO2006033911A2 (en) 2004-09-17 2006-03-30 Mgi Gp, Inc. Methods of administering water-soluble prodrugs of propofol
EP1844000B1 (en) 2004-12-23 2010-01-27 Xenoport, Inc. Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
DE102005033496A1 (de) * 2005-07-19 2007-01-25 Bayer Healthcare Ag Desinfektionsmittel
JP5537033B2 (ja) * 2005-12-19 2014-07-02 ザ ユニヴァーシティー オブ リヴァプール 無痛覚
US7535698B2 (en) 2006-03-07 2009-05-19 Panasonic Corporation Case, portable information equipment using the same and manufacturing method of the case
US7731356B1 (en) * 2006-07-24 2010-06-08 Daniel Ayers Gilbert Hanging eyeglasses

Similar Documents

Publication Publication Date Title
JP2010526827A5 (enExample)
RU2009145541A (ru) Терапевтические соединения
JP2013534248A5 (enExample)
JP2009542613A5 (enExample)
JP2017533964A5 (enExample)
JP2010526826A5 (enExample)
JP2013541514A5 (enExample)
JP2003532731A5 (enExample)
JP2010520306A5 (enExample)
JP2013545730A5 (enExample)
JP2006506425A5 (enExample)
JP2010138190A5 (enExample)
JP2009531277A5 (enExample)
JP2005529840A5 (enExample)
JP2011507896A5 (enExample)
RU99112115A (ru) Энантиомерно чистые основные эфиры арил-циклоалкилгидроксикарбоновых кислот, способ их получения и применение в лекарственных средствах
JP2011518202A5 (enExample)
JP2005539045A5 (enExample)
JP2012530779A5 (enExample)
JP2014505017A5 (enExample)
JP2013533253A5 (enExample)
JP2020505354A5 (enExample)
JP2012510985A5 (enExample)
JP2005536503A5 (enExample)
JP2012144537A5 (enExample)